Pfizer Inc. (PFE) Shares Sold by SSI Investment Management Inc.

SSI Investment Management Inc. reduced its position in Pfizer Inc. (NYSE:PFE) by 1.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,296 shares of the biopharmaceutical company’s stock after selling 422 shares during the period. SSI Investment Management Inc.’s holdings in Pfizer were worth $789,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in PFE. Fusion Family Wealth LLC purchased a new stake in Pfizer during the fourth quarter worth $109,000. First National Bank Sioux Falls increased its stake in Pfizer by 108.2% in the third quarter. First National Bank Sioux Falls now owns 3,367 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 1,750 shares during the period. Gierl Augustine Investment Management Inc increased its stake in Pfizer by 5.8% in the third quarter. Gierl Augustine Investment Management Inc now owns 3,718 shares of the biopharmaceutical company’s stock worth $126,000 after buying an additional 205 shares during the period. Stanford Investment Group Inc. increased its stake in Pfizer by 11.8% in the fourth quarter. Stanford Investment Group Inc. now owns 4,329 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 456 shares during the period. Finally, Nelson Roberts Investment Advisors LLC increased its stake in Pfizer by 53.1% in the third quarter. Nelson Roberts Investment Advisors LLC now owns 4,590 shares of the biopharmaceutical company’s stock worth $155,000 after buying an additional 1,591 shares during the period. Hedge funds and other institutional investors own 69.53% of the company’s stock.

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) traded down 0.30% during trading on Friday, reaching $33.64. 25,471,151 shares of the company’s stock traded hands. The firm has a 50 day moving average price of $34.16 and a 200-day moving average price of $32.82. Pfizer Inc. has a 12 month low of $29.83 and a 12 month high of $37.39. The firm has a market cap of $200.22 billion, a PE ratio of 28.68 and a beta of 0.94. Pfizer also saw some unusual options trading activity on Tuesday. Stock traders bought 976 call options on the company. This represents an increase of 131% compared to the typical volume of 422 call options.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 31st. The biopharmaceutical company reported $0.47 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by $0.03. Pfizer had a net margin of 13.50% and a return on equity of 23.18%. The firm earned $13.60 billion during the quarter, compared to the consensus estimate of $13.64 billion. During the same quarter last year, the business posted $0.53 earnings per share. Pfizer’s revenue was down 3.0% compared to the same quarter last year. On average, analysts forecast that Pfizer Inc. will post $2.55 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was published by BBNS and is owned by of BBNS. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://baseballnewssource.com/markets/ssi-investment-management-inc-has-789000-position-in-pfizer-inc-pfe-updated-updated/525631.html.

PFE has been the subject of a number of recent research reports. Vetr downgraded Pfizer from a “strong-buy” rating to a “buy” rating and set a $36.33 price objective for the company. in a research report on Monday, December 26th. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $36.00 price objective for the company in a research report on Tuesday, January 3rd. Goldman Sachs Group Inc set a $36.00 price objective on Pfizer and gave the company a “neutral” rating in a research report on Wednesday, January 18th. Jefferies Group LLC reiterated a “hold” rating and set a $30.00 price objective on shares of Pfizer in a research report on Thursday, January 19th. Finally, Piper Jaffray Companies set a $53.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Saturday, January 21st. Thirteen equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $37.57.

In other Pfizer news, insider Charles H. Hill sold 36,000 shares of Pfizer stock in a transaction that occurred on Thursday, March 9th. The shares were sold at an average price of $34.07, for a total transaction of $1,226,520.00. Following the completion of the sale, the insider now directly owns 57,329 shares in the company, valued at $1,953,199.03. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Rady A. Johnson sold 4,500 shares of Pfizer stock in a transaction that occurred on Friday, March 10th. The shares were sold at an average price of $34.19, for a total transaction of $153,855.00. Following the sale, the insider now owns 54,963 shares of the company’s stock, valued at $1,879,184.97. The disclosure for this sale can be found here. Insiders sold 71,470 shares of company stock valued at $2,449,150 over the last 90 days. 0.07% of the stock is owned by company insiders.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

5 Day Chart for NYSE:PFE

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with our FREE daily email newsletter.

 

Latest News

Sources Say Luis Robert Will Be Cleared by May 20 to Sign
Sources Say Luis Robert Will Be Cleared by May 20 to Sign
Colorado Rockies Bullpen Helping Them to NL West Lead
Colorado Rockies Bullpen Helping Them to NL West Lead
Hall of Famer Given New Lease on Life
Hall of Famer Given New Lease on Life
New York Mets Have the Power
New York Mets Have the Power
Red Sox Fighting Through Illness and Injury
Red Sox Fighting Through Illness and Injury
Cleveland and Arizona Off to Fast Starts
Cleveland and Arizona Off to Fast Starts


Leave a Reply

 
© 2006-2017 BBNS.